APOE interacts with ACE2 inhibiting SARS-CoV-2 cellular entry and inflammation in COVID-19 patients

• Published in: Signal transduction and targeted therapy Vol. 7; no. 1; pp. 261 - 9
• Main Authors: Zhang, Hongsheng, Shao, Lin, Lin, Zhihao, Long, Quan-Xin, Yuan, Huilong, Cai, Lujian, Jiang, Guangtong, Guo, Xiaoyi, Yang, Renzhi, Zhang, Zepeng, Zhang, Bingchang, Liu, Fan, Li, Zhiyong, Ma, Qilin, Zhang, Yun-Wu, Huang, Ai-Long, Wang, Zhanxiang, Zhao, Yingjun, Xu, Huaxi
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 01.08.2022; Nature Publishing Group
• Subjects: 631/250/255; 692/699/255; ACE2; Angiotensin-converting enzyme 2; Apolipoprotein E; Apolipoprotein E4; Cancer Research; Cardiovascular diseases; Cell Biology; Chemokines; Cholesterol; Coronaviruses; COVID-19; Cytokines; Disease transmission; Infections; Inflammation; Internal Medicine; Isoforms; Lipid metabolism; Medicine; Medicine & Public Health; Metalloproteinase; Oncology; Pathology; Risk factors; Severe acute respiratory syndrome coronavirus 2; Spike protein

Apolipoprotein E (APOE) plays a pivotal role in lipid including cholesterol metabolism. The APOE ε4 (APOE4) allele is a major genetic risk factor for Alzheimer’s and cardiovascular diseases. Although APOE has recently been associated with increased susceptibility to infections of several viruses, wh...